Emerge Diagnostics is a global medical services brand that specializes in the diagnosis and treatment of soft tissue injuries. With a mission to help people return to work and life faster, they offer Electrodiagnostic Functional Assessment (EFA) programs that have been utilized by numerous major employers worldwide for the past decade. These programs have proven to significantly improve outcomes for workplace injuries.

Emerge Diagnostics recently introduced enhancements to their program, enabling the delivery of comprehensive testing and ongoing monitoring through objective telemedicine evaluations. Their EFA technology combines five diagnostic tests accepted by the American Medical Association into a single, reliable, and comprehensive test. This helps patients, employers, and healthcare providers obtain accurate results and facilitate faster recovery.

The brand is led by Bret Oettmeier, CEO, who has a wealth of experience in investing in healthcare companies. Dr. Mary Rose Reaston, the co-founder and Chief Scientific Officer, is a pioneer in using electrodiagnostic tools for better injury diagnosis.

Sheila Harless, the Director of Operations, brings extensive experience in patient triage and insurance reimbursement. Connect with Emerge Diagnostics on their social media platforms, including Facebook, Instagram, LinkedIn, Twitter, and YouTube, to stay updated with their latest innovations and advancements in the field of soft tissue injury diagnosis and treatment